← Latest news 
Eli Lilly launches monthly Alzheimer drug Lormalzi in India at ₹91,688 per vial
Entertainment
Published on 13 May 2026
A monthly dose now targets brain amyloid plaques
Eli Lilly has launched Lormalzi, a monthly treatment for early Alzheimer’s disease, in India. The therapy targets amyloid plaques and is set to be available this month. Positioned as part of the company’s broader push in specialty medicines, Lormalzi comes with a steep price tag of ₹91,688 per vial. The move signals rising focus on Alzheimer’s innovation in India.
- Eli Lilly introduces Lormalzi for early Alzheimer’s in India
- The monthly therapy targets amyloid plaques
- It will be available in India this month
- Pricing is set at ₹91,688 per vial
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times